Triple-negative breast cancer: Role of specific chemotherapy agents

Cancer Journal

Volumn 16, Issue 1, 2010, Pages 53-61

  Isakoff, Steven J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Basal like breast cancer; Carboplatin; Chemotherapy; Cisplatin; Metastatic; Neoadjuvant; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IXABEPILONE; METHOTREXATE; MITOMYCIN; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SELECTIVITY; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77149138342     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181d24ff7     Document Type: Review

References (76)

1. Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44:2799 -2805.
2. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9:29 -33.
3. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638-2645.
4. Sledge G, Miller K, Moisa C, et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol. 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 supplement):1013.
5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
6. Lippman ME, Allegra JC, Thompson EB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med. 1978;298:1223-1228.
7. Kiang DT, Frenning DH, Goldman AI, et al. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med. 1978;299:1330-1334.
8. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371:29-40.
9. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658-1667.
10. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21:1431-1439.
11. Gluz O, Nitz UA, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol. 2008;19:861-870.
12. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
13. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037-1044.
14. Wang S, Yang H, Tong F, et al. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To kagaku Ryoho. 2009;36:255-258.
15. Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91:2012-2017.
16. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10:6622-6628.
17. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174.
18. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785.
19. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23: 2676-2685.
20. Darb-Esfahani S, Loibl S, Muller BM, et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 2009;11:R69.
21. Esserman LJ, Perou C, Cheang M, et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). J Clin Oncol. 2009;27:18S (suppl; abstr LBA515).
22. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11: 5678-5685.
23. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13: 2329-2334.
24. Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007;7:203.
25. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev. 2004;30:53-81.
26. Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1983;11:108-112.
27. Mechl Z, Sopkova B. CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma. 1984;31:431-435.
28. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 1988;6:1811-1814.
29. Bajorin D, Bosl GJ, Fein R. Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol. 1987;5:1589-1593.
30. Forastiere AA, Hakes TB, Wittes JT, et al. Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol. 1982;5:243-247.
31. Martino S, Samal BA, Singhakowinta A, et al. A phase II study of cisdiamminedichloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol. 1984;108:354-356.
32. Ostrow S, Egorin M, Aisner J, et al. High-dose cis- diamminedichloroplatinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials. 1980;3:23-27.
33. Yap HY, Salem P, Hortobagyi GN, et al. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep. 1978;62: 405-408.
34. Crown JP. The platinum agents: a role in breast cancer treatment? Semin Oncol. 2001;28(1 suppl 3):28-37.
35. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol. 2000;18: 287-295.
36. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
37. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000;275:23899-23903.
38. Husain A, He G, Venkatraman ES, et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 1998;58:1120-1123.
39. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001;61:4842-4850.
40. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003;63:6221-6228.
41. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285-1291.
42. Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene. 2001;20:6597-6606.
43. Leong CO, Vidnovic N, Deyoung MP, et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 2007;117:1370-1380.
44. Uhm JE, Park YH, Yi SY, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer. 2009;124:1457-1462.
45. Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). In: 2006 San Antonio Breast Cancer Symposium, San Antonio, TX; 2006: Abstract #3074.
46. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast. J Clin Oncol. In press.
47. Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol. 2009;27:15S (suppl; abstr 551).
48. Ezzat AA, Ibrahim EM, Ajarim DS, et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer. 2004;90:968-974.
49. Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatinepirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol. 2009;20:1185-1192.
50. Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol. 2008;62:667-672.
51. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008;19:1847-1852.
52. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115:359-363.
53. Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol. 2009;27:15S (suppl; abstr 502).
54. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 2008;26:15S (May 20 suppl; abstr 1009).
55. Isakoff SJ, Leong C, Vidnovic N, et al. p63/p73 expression mediates cisplatin sensitivity in a subset of triple-negative primary breast cancer: implications for a new clinical trial. J Clin Oncol. 2007;25:10522.
56. Byrski T, Foszczynska-Kloda M, Huzarski T, et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). J Clin Oncol. 2009;27:15S (suppl; abstr 1099).
57. Kilburn LS. 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol). 2008;20:35-39.
58. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
59. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496-1506.
60. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-1671.
61. Mazouni C, Kau SW, Frye D, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007;18: 874-880.
62. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168-1176.
63. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med. 2005;352:2302-2313.
64. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686-3696.
65. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108:289-296.
66. Wysocki PJ, Korski K, Lamperska K, et al. Primary resistance to docetaxelbased chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit. 2008;14:SC7-SC10.
67. Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006;8:R66.
68. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
69. Pinilla SM, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat. 2006;99:85-90.
70. Altundag K, Harputluoglu H, Aksoy S, et al. Potential chemotherapy options in the triple negative subtype of breast cancer. J Clin Oncol. 2007;25:1294-1295; author reply 1295-1296.
71. Petit T, Wilt M, Rodier J, et al. Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers? J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 supplement):580.
72. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002;39:608-610.
73. Cheang M, Chia SK, Tu D, et al. Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol. 2009;27:15S (suppl; abstr 519).
74. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360:2055-2065.
75. Rugo HS, Roche H, Thomas E, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. In: San Antonio Breast Cancer Symposium, San Antonio, TX; 2008: Abstract #3057.
76. Mehta RS. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol. 2008;26:3286-3288.